Estradiol/levonorgestrel continuous transdermal - Merck KGaA

Drug Profile

Estradiol/levonorgestrel continuous transdermal - Merck KGaA

Alternative Names: EMD 90171; Fem7 Plus; Fem7® Conti

Latest Information Update: 23 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer AbbVie
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Norpregnanes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories
  • 09 Apr 2009 No development reported - Phase-III for Menopausal syndrome in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top